Simões-Wüst Ana Paula, Jeschke Elke, Mennet Mónica, Schnelle Martin, Matthes Harald, von Mandach Ursula
Research Department, Paracelsus Hospital, Richterswil, Switzerland.
Forsch Komplementmed. 2012;19(6):293-301. doi: 10.1159/000345841. Epub 2012 Dec 17.
The use of preparations from Bryophyllum pinnatum for tocolysis (or to arrest labor) is supported by observations obtained mainly at empirical level, but also by preclinical experiments performed with uterus strips and myometrium cell lines. Furthermore, a retrospective matched-pair study revealed good tolerability and effectiveness. In anthroposophic medicine, however, Bryophyllum species are used for a broad spectrum of diagnoses. Here, we characterize the prescribing pattern of Bryophyllum preparations in a network of anthroposophic physicians in Germany.
38 primary-care physicians in Germany participated in the EvaMed network, a multi-center observational study. They documented anonymized prescriptions, diagnoses and demographic data (age and gender) for each consecutive patient between 01.01.2004 and 01.01.2010. Diagnoses were coded according to the 10th revision of the International Classification of Diseases (ICD-10). In the present analysis, all prescriptions of any Bryophyllum preparation in the resulting data bank were identified and the corresponding diagnoses were analyzed retrospectively.
A total of 4,038 prescriptions of Bryophyllum preparations were identified in the EvaMed data bank. A variety of preparations could be found, 77.7% of which were prepared from Bryophyllum plants exclusively and 22.5% were combinations. Bryophyllum preparations were often prescribed to treat 'mental and behavioral disorders' (ICD-10 F00-F99, 35.7%) and 'diseases of the skin and subcutaneous tissue' (L00-L99, 16.0%), followed by 'symptoms, signs, and abnormal clinical and laboratory findings, not elsewhere classified diseases' (R00-R99, 15.2%) and 'diseases of the nervous system' (G00- G99, 9.7%).
By revealing the use of Bryophyllum preparations in so many other indications than preterm delivery, our data clearly show the urgent need to conduct additional clinical trials.
使用落地生根属植物制剂进行安胎（或抑制宫缩）主要是基于经验观察，同时子宫肌条和子宫肌层细胞系的临床前实验也为此提供了支持。此外，一项回顾性配对研究表明其耐受性良好且效果显著。然而，在人智医学中，落地生根属植物被用于多种诊断。在此，我们描述了德国一群人智医学医生网络中落地生根属植物制剂的处方模式。
德国38名初级保健医生参与了一项多中心观察性研究EvaMed网络。他们记录了2004年1月1日至2010年1月1日期间每位连续就诊患者的匿名处方、诊断和人口统计学数据（年龄和性别）。诊断按照《国际疾病分类》第10版（ICD - 10）进行编码。在本分析中，识别了数据库中所有落地生根属植物制剂的处方，并对相应诊断进行回顾性分析。
在EvaMed数据库中总共识别出4038份落地生根属植物制剂的处方。发现了多种制剂，其中77.7%仅由落地生根属植物制备，22.5%是复方制剂。落地生根属植物制剂常被用于治疗“精神和行为障碍”（ICD - 10 F00 - F99，35.7%）和“皮肤及皮下组织疾病”（L00 - L99，16.0%），其次是“症状、体征及临床和实验室检查异常，未在他处分类的疾病”（R00 - R99，15.2%）和“神经系统疾病”（G00 - G99，9.7%）。
我们的数据表明，除早产外，落地生根属植物制剂还被用于许多其他适应症，这清楚地表明迫切需要进行更多临床试验。
